Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CASR | P41180 | 1/20 | 0.35 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5480635 | 0.89 | ADRA1D (0.45) | LDHAACACBMEN1KMT2ATRIM24 | |
| SCHEMBL4356427 | 0.89 | ADRA1D (0.45) | LDHAACACBMEN1KMT2ATRIM24 | |
| SCHEMBL13623721 | 0.82 | LDHA (0.46) | LDHAACACBMEN1KMT2AALDH1A1 | |
| SCHEMBL13623710 | 0.79 | TRPV4 (0.40) | LDHATRIM24ALDH1A1 | |
| SCHEMBL14039804 | 0.76 | LDHA (0.40) | LDHAACACBMEN1KMT2AALDH1A1 | |
| SCHEMBL4367393 | 0.75 | ACACB (0.56) | LDHAACACBKMT2AALDH1A1 | |
| SCHEMBL24503566 | 0.75 | TRPV4 (0.45) | LDHATRIM24ALDH1A1 | |
| SCHEMBL5903990 | 0.74 | ACACB (0.45) | LDHAACACBMEN1KMT2ATRIM24 | |
| SCHEMBL5807725 | 0.74 | ACACB (0.45) | LDHAACACBMEN1KMT2ATRIM24 | |
| SCHEMBL30997420 | 0.73 | CA5A (0.47) | MEN1KMT2ALMNAALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7619116-B2 | Intermediates for the synthesis of (R)-tamsulosin and of its pharmaceutically acceptable salts and process for their preparation | Products Chimiques Auxiliaires Et de Synthese (FR) | 2009-11-17 | — | — | US | disclosed |
| EP-1697316-B1 | NOVEL INTERMEDIATES FOR THE SYNTHESIS OF (R)-TAMSULOSIN AND OF ITS PHARMACEUTICALLY ACCEPTABLE SALTS AND PROCESS FOR THEIR PREPARATION | PROD CHIM AUXILIAIRES ET DE SY (FR) | 2008-10-08 | — | — | EP | disclosed |
| US-20070106079-A1 | Novel intermediates for the synthesis of (r)-tamsulosin and of its pharmaceutically acceptable salts and process for their preparation | PRODUITS CHIMIQUES AUXILIAIRES ET DE SYNTHESE (FR) | 2007-05-10 | — | — | US | disclosed |
| EP-1697316-A1 | NOVEL INTERMEDIATES FOR THE SYNTHESIS OF (R)-TAMSULOSIN AND OF ITS PHARMACEUTICALLY ACCEPTABLE SALTS AND PROCESS FOR THEIR PREPARATION | PRODUITS CHIMIQUES AUXILIAIRES ET DE SYNTHESE (FR) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005058810-A1 | NOVEL INTERMEDIATES FOR THE SYNTHESIS OF (R)-TAMSULOSIN AND OF ITS PHARMACEUTICALLY ACCEPTABLE SALTS AND PROCESS FOR THEIR PREPARATION | PRODUITS CHIMIQUES AUXILIAIRES ET DE SYNTHESE (FR) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070106079-A1 | Novel intermediates for the synthesis of (r)-tamsulosin and of its pharmaceutically acceptable salts and process for their preparation | ADRB1, AVPR2, ADRA1A | LDHA 3340/4885ACACB 3915/4885MEN1 475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.